↓ Skip to main content

Don’t sell out safety: a call to preserve risk evaluation and mitigation strategies to reduce harm to patients and the public in the U.S.

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, January 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 110)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
3 news outlets
blogs
1 blog
twitter
2 tweeters

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Don’t sell out safety: a call to preserve risk evaluation and mitigation strategies to reduce harm to patients and the public in the U.S.
Published in
Journal of Pharmaceutical Policy and Practice, January 2016
DOI 10.1186/s40545-016-0051-0
Pubmed ID
Authors

Stacey L. Worthy

Abstract

As medicines are becoming more targeted and complex in the U.S., ensuring patients' safe use of medications with known dangerous risks is critical for public health and safety. Therefore, the Risk Evaluation and Mitigation Strategies (REMS) program is more important than ever. The REMS programs mandates that manufacturers utilize tools to manage known or potential serious risks (e.g., death, severe birth defects, prolonged hospitalization) associated with certain drugs while still making these medications available to patients with unmet medical needs. Yet, recently federal policy makers have proposed legislation to force manufacturers to sell medications with known serious risks in a manner that weakens the medications' REMS programs. The author reviewed U.S. legislation, statutes, case law, government agency policies and guidelines, scholarly articles, and news stories published between January 1, 2004 and December 1, 2015 and provided legal and policy analysis. REMS are necessary to make medications with known severe risks available to certain patient populations for whom treatment may not be available otherwise. In order to ensure that proper safety measures are preserved and medications with known risks are not diverted to parties who will not follow safety requirements, legislation should not be passed to require a forced sale of drugs subject to REMS with restricted distribution for bioequivalence testing purposes. Generic manufacturers must be held to the same REMS safety standards as brand manufacturers. Systems currently in place adequately balance risk and safety.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 4 29%
Student > Master 4 29%
Student > Ph. D. Student 2 14%
Student > Bachelor 1 7%
Researcher 1 7%
Other 2 14%
Readers by discipline Count As %
Medicine and Dentistry 5 36%
Unspecified 4 29%
Pharmacology, Toxicology and Pharmaceutical Science 2 14%
Immunology and Microbiology 1 7%
Psychology 1 7%
Other 1 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2016.
All research outputs
#251,677
of 7,896,890 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#3
of 110 outputs
Outputs of similar age
#15,847
of 327,126 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#1
of 5 outputs
Altmetric has tracked 7,896,890 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 110 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,126 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them